A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Phase 1
87
about 4.1 years
18+
34 sites in FL, GA, IN +8
What this study is about
Researchers are testing a treatment combination of elranatamab and iberdomide to see if it's safe and tolerable for people with relapsed or refractory multiple myeloma. The trial will also determine the correct dose of this combination for these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Elranatamab
- 2.Take Iberdomide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
elranatamab
Primary: Part 1: Number of participants with dose limiting toxicity (DLT), Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Secondary: Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity, Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities, Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR), Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR), Part 1 and Part 2: Time of Overall Survival (OS), Part 1 and Part 2: Time of Progression Free Survival (PFS), Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Oncology